Kardios Cardiología

26/06/2025

No mas bariátricas....

21/06/2025

The FDA has approved Widaplik, a triple-drug combination, for the treatment of hypertension in adults. It combines 3 drugs( telmisartan, amlodipine, indapamide) in a single pill.

29/05/2025

ibuprofen should be given at least 30 minutes or longer after aspirin ingestion, or more than 8 hours before aspirin ingestion to avoid attenuation of aspirin’s effect.

14/05/2025

SGLT2 inhibitors increase both hemoglobin and hematocrit levels in T2DM patients with CKD and HF

02/05/2025

03/04/2025

Los iSGLT2 puede provocar tos seca y dolor de vejiga.

17/03/2025

Estenosis Aórtica severa.

13/03/2025

*Famous causes of Dyspnea/Effort intolerance/ Fatigue.*

Acid: DKA , Acute renal failure, Acid reflux (Hiatus Hernia).

Anemia/Iron deficiency without anemia

Anxiety: Hyperventilation

Body weight: Recent increase in body weight(obesity)

Blood Pressure: Hypertension uncontrolled.

P: Pulmonary Embolism, Pulmonary causes

C: Cardiac problem

D: Depression

D: Vitamin D deficiency
Drug: Ticagrelor

E: Elevated or decreased TSH(Hypothyroidism or hyperthyroidism)

08/03/2025

Dosificación de la Warfarina según INR

28/02/2025

Here is a summary of the key changes in the 2025 ACC/AHA/ACEP/NAEMSP/SCAI

Guideline for the Management of Patients With Acute Coronary Syndromes compared to previous guidelines:

1. *Dual Antiplatelet Therapy (DAPT) Updates*
Shortened DAPT duration: Transition to ticagrelor monotherapy after 1 month post-PCI is now recommended in selected patients to reduce bleeding risk​
Clopidogrel monotherapy caution: The use of clopidogrel monotherapy after early aspirin discontinuation may increase major adverse cardiovascular events (MACE) risk​
2. *Updated PCI and CABG Recommendations*
STEMI patients with multivessel disease (MVD): PCI of non-culprit lesions is recommended after infarct-related artery PCI to reduce death and MI​
No routine non-culprit PCI in cardiogenic shock: Routine PCI of non-culprit lesions in STEMI with cardiogenic shock is discouraged due to increased mortality risk​
3. *Lipid Management Enhancements*
Stronger emphasis on LDL-C control: Patients with LDL-C ≥70 mg/dL despite high-intensity statin should receive additional non-statin lipid-lowering therapy (e.g., ezetimibe, PCSK9 inhibitors)​
4. *Anticoagulation in STEMI*
Enoxaparin preferred over UFH in STEMI patients receiving fibrinolysis if no PCI planned​
Fondaparinux is an alternative for STEMI patients unlikely to undergo invasive treatment​
5. *Expanded Role of Imaging in PCI*
IVUS/OCT-guided PCI recommended for complex lesions to reduce stent thrombosis and target vessel failure​
6. *Emphasis on Cardiac Rehabilitation*
Home-based cardiac rehab programs are now recognized as a reasonable alternative to center-based programs​